Third Pole Therapeutics specializes in the advancement and provision of crucial cardio-pulmonary treatments. Dr. Warren Zapol, the founder of Third Pole, developed the initial application of inhaled nitric oxide (iNO) for addressing hypoxic respiratory failure in neonatal infants (cyanotic newborns). Subsequently, in addition to cyanotic newborns, numerous pediatric and adult patients with heightened pulmonary pressure, inflammation, and inadequate oxygen levels during and after cardiac surgery have benefited from inhaled nitric oxide treatment. This has led to the emergence of a $600 million market for inhaled nitric oxide, predominantly concentrated in major hospitals and developed economies.
Third Pole Therapeutics
Headquarters
United States of America